Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

August 20, 2020

#2 At virtual ASCO 2020, Dr. John Byrd led a group of researchers to report the latest from the first phase 2 study of acalabrutinib, ACE-CL-001 (NCT02029443), a next-generation BTK inhibitor, which is now approved for CLL patients, both treatment-naïve as well as those with relapsed/refractory disease.